menu search

Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update

Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
Further analysis of results from recently-completed SUMMIT Phase 3 efficacy trial of STS101 for the acute treatment of migraine shows differentiating robust and sustained antimigraine effects on clinically important secondary endpoints Qualitative and quantitative primary market research conducted post-SUMMIT trial readout and incorporating updated STS101 profile consistent with SUMMIT trial results indicates headache specialists continue […] The post Satsuma Pharmaceuticals Provides STS101 Deve... Read More
Posted: Dec 20 2022, 14:21
Author Name: forextv
Views: 101987

Search within

Pages Search Results: